Arie Belldegrun, M.D.

Edit your Faculty Profile
Work Titles
UCLA Professor, Urology Surgical Director, Genitourinary Oncology Physician, Bladder Cancer Program Physician, Prostate Research and Treatment Program Physician, Testicular Cancer Program Surgical Director, Kidney Cancer Program Member, JCCC Genitourinary Oncology Program Area
Education:
Degrees:
M.D., Hebrew University Hadassah Medical School, 1974
Fellowship:
1985 - 1988 National Institutes of Health, The Clinical Center
1976 - 1979 Weizmann Institute of Science
Residency:
1982 - 1985 Brigham & Women's Hospital
1980 - 1982 Beilinson Hospital
1979 - 1980 Beilinson Hospital
Certifications:
Certifications:
1999 American Board of Urology
1991 American Board of Urology

Contact Information:

Work Email Address:

abelldegrun@mednet.ucla.edu


Website:

Web-Profile

Fax Number:

310-794-3513

Mailing Address:

UCLA Urology/Sch of Med
BOX 957384
924 Westwd Bl, Ste 1050
Los Angeles, CA 90095


Work Address:

66-118 CHS
CAMPUS - 173818
CA


Publications:

A selected list of publications:

Lam JS, Leppert JT, Figlin RA, Belldegrun AS   Surveillance following radical or partial nephrectomy for renal cell carcinoma Curr Urol Rep, 2005; 6(1): 7-18.
Shi T, Seligson D, Belldegrun AS, Palotie A, Horvath S   Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. , 2005; 18(4): 547-57.
Zeng G, Aldridge ME, Wang Y, Pantuck AJ, Wang AY, Liu YX, Han Y, Yuan YH, Robbins PF, Dubinett SM, Dekernion JB, Belldegrun AS   Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: Implications as a potential biomarker Int J Cancer, 2005; 114(2): 268-73.
Lam JS, Belldegrun AS, Figlin RA   Advances in immune-based therapies of renal cell carcinoma Expert review of anticancer therapy. , 2004; 4(6): 1081-96.
Lam JS, Belldegrun AS, Figlin RA   Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy Clinical cancer research : an official journal of the American Association for Cancer Research. , 2004; 10(18 Pt 2): 6304S-9S.
Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han KR, Cindolo L, De La Taille A, Tostain J, Artibani W, Dinney CP, Wood CG, Swanson DA, Abbou CC, Lobel B, Mulders PF, Chopin DK, Figlin RA, Belldegrun AS   Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study Journal of clinical oncology : official journal of the American Society of Clinical Oncology. , 2004; 22(16): 3316-22.
Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Figlin RA, Horvath S, Belldegrun AS   Using protein expressions to predict survival in clear cell renal carcinoma Clinical cancer research : an official journal of the American Association for Cancer Research. , 2004; 10(16): 5464-71.
Liu AY, Brubaker KD, Goo YA, Quinn JE, Kral S, Sorensen CM, Vessella RL, Belldegrun AS, Hood LE   Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines The Prostate. , 2004; 60(2): 98-108.
Han KR, Janzen NK, McWhorter VC, Kim HL, Pantuck AJ, Zisman A, Figlin RA, Dorey FJ, Said JW, Belldegrun AS   Cystic renal cell carcinoma: biology and clinical behavior Urologic oncology. , 2004; 22(5): 410-4.
Pantuck AJ, Van Ophoven A, Gitlitz BJ, Tso CL, Acres B, Squiban P, Ross ME, Belldegrun AS, Figlin RA   Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer Journal of immunotherapy (Hagerstown, Md. : 1997) , 2004; 27(3): 240-53.
Patard JJ, Dorey FJ, Cindolo L, Ficarra V, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Belldegrun AS, Pantuck AJ   Symptoms As Well As Tumor Size Provide Prognostic Information On Patients With Localized Renal Tumors J Urol, 2004; 172(6, Part 1 of 2): 2167-2171.
Bui MH, Visapaa H, Seligson D, Kim H, Han KR, Huang Y, Horvath S, Stanbridge EJ, Palotie A, Figlin RA, Belldegrun AS   Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma The Journal of urology. , 2004; 171(6 Pt 1): 2461-6.
Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, Cindolo L, Han KR, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Mulders PF, Belldegrun AS   Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience The Journal of urology. , 2004; 171(6 Pt 1): 2181-5, quiz 2435.
Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS   Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma The Journal of urology. , 2004; 171(5): 1810-3.
Han KR, Kim HL, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun AS   Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma Urology. , 2004; 63(5): 841-6; discussion 846-7.
Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui MH, Han KR, Correa AJ, Eeva M, Tze S, Belldegrun AS, Figlin RA   Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma Clinical cancer research : an official journal of the American Association for Cancer Research. , 2004; 10(8): 2659-69.
Mukouyama H, Janzen NK, Hernandez JM, Lam JS, Caliliw R, Wang AY, Figlin RA, Belldegrun AS, Zeng G   Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9 Clin Cancer Res, 2004; 10(4): 1421-9.
Shvarts O, Lam J, Figlin R, Belldegrun AS   Heat shock-peptide complex vaccine as adjuvant therapy for high-risk patients with resected renal cell carcinoma Current urology reports. , 2004; 5(1): 11-2.
Lam JS, Shvarts O, Belldegrun AS   Kidney cancer management in 2004: an update for the practicing general urologist Current urology reports. , 2004; 5(1): 1-3.
Kim HL, Zisman A, Han KR, Figlin RA, Belldegrun AS   Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? The Journal of urology. , 2004; 171(2 Pt 1): 588-91.
Kim HL, Lam JS, Belldegrun AS   The role of lymphadenectomy in renal cell carcinoma Current urology reports. , 2004; 5(1): 25-9.
Han KR, Belldegrun AS   Third-generation cryosurgery for primary and recurrent prostate cancer BJU international. , 2004; 93(1): 14-8.
Han KR, Bleumer I, Pantuck AJ, Kim HL, Dorey FJ, Janzen NK, Zisman A, Dinney CP, Wood CG, Swanson DA, Said JW, Figlin RA, Mulders PF, Belldegrun AS   Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population The Journal of urology. , 2003; 170(6 Pt 1): 2221-4.
Kim HL, Belldegrun AS, Freitas DG, Bui MH, Han KR, Dorey FJ, Figlin RA   Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis The Journal of urology. , 2003; 170(5): 1742-6.
Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA   Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway Clinical cancer research : an official journal of the American Association for Cancer Research. , 2003; 9(13): 4641-52.
Han KR, Cohen JK, Miller RJ, Pantuck AJ, Freitas DG, Cuevas CA, Kim HL, Lugg J, Childs SJ, Shuman B, Jayson MA, Shore ND, Moore Y, Zisman A, Lee JY, Ugarte R, Mynderse LA, Wilson TM, Sweat SD, Zincke H, Belldegrun AS   Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience The Journal of urology. , 2003; 170(4 Pt 1): 1126-30.
Palapattu GS, Pantuck AJ, Dorey F, Said JW, Figlin RA, Belldegrun AS   Collecting system invasion in renal cell carcinoma: impact on prognosis and future staging strategies The Journal of urology. , 2003; 170(3): 768-72; discussion 772.
Zisman A, Pantuck AJ, Bui MH, Said JW, Caliliw RR, Rao N, Shintaku P, Berger F, Gambhir SS, Belldegrun AS   LABAZ1: A metastatic tumor model for renal cell carcinoma expressing the carbonic anhydrase type 9 tumor antigen Cancer research. , 2003; 63(16): 4952-9.
Gitlitz BJ, Belldegrun AS, Zisman A, Chao DH, Pantuck AJ, Hinkel A, Mulders P, Moldawer N, Tso CL, Figlin RA   A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma Journal of immunotherapy (Hagerstown, Md. : 1997) , 2003; 26(5): 412-9.
Han KR, Pantuck AJ, Belldegrun AS   Basic biology and clinical behavior of renal cell carcinoma Cancer treatment and research. , 2003; 116: 69-89.
Kim HL, Pantuck AJ, Zomorodian N, Belldegrun AS   Monoclonal antibody (MAB) in patients with advanced cancer Curr Urol Rep, 2003; 4(1): 11-2.
Hernandez JM, Bui MH, Han KR, Mukouyama H, Freitas DG, Nguyen D, Caliliw R, Shintaku PI, Paik SH, Tso CL, Figlin RA, Belldegrun AS   Novel kidney cancer immunotherapy based on the granulocyte-macrophage colony-stimulating factor and carbonic anhydrase IX fusion gene Clin Cancer Res, 2003; 9(5): 1906-16.
Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz B, Belldegrun AS, Figlin RA   Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy Cancer. , 2003; 97(12): 2995-3002.
Janzen NK, Kim HL, Figlin RA, Belldegrun AS   Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease Urol Clin North Am, 2003; 30(4): 843-52.
Han KR, Bui MH, Pantuck AJ, Freitas DG, Leibovich BC, Dorey FJ, Zisman A, Janzen NK, Mukouyama H, Figlin RA, Belldegrun AS   TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion J Urol, 2003; 169(3): 899-903; discussion 903-4.
Freedland SJ, Pantuck AJ, Paik SH, Zisman A, Graeber TG, Eisenberg D, McBride WH, Nguyen D, Tso CL, Belldegrun AS   Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system Prostate, 2003; 55(4): 299-307.
Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz BJ, Figlin RA, Belldegrun AS   Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection The Journal of urology. , 2003; 169(6): 2076-83.
Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS   Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer The Prostate. , 2003; 55(1): 71-80.
Zisman A, Wieder JA, Pantuck AJ, Chao DH, Dorey F, Said JW, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS   Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy The Journal of urology. , 2003; 169(3): 909-16.
Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS   Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy Clinical cancer research : an official journal of the American Association for Cancer Research. , 2003; 9(2): 802-11.
Kim HL, Belldegrun AS, Figlin RA   Immune gene therapy for kidney cancer: the search for a magic trigger Molecular therapy : the journal of the American Society of Gene Therapy. , 2003; 7(2): 153-4.
Han KR, Pantuck AJ, Bui MH, Shvarts O, Freitas DG, Zisman A, Leibovich BC, Dorey FJ, Gitlitz BJ, Figlin RA, Belldegrun AS   Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma Urology. , 2003; 61(2): 314-9.

Does this profile need updating? Contact Us